- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
Health technology assessment (HTA) is a tool that helps to objectively evaluate evidence, which levels the playing field for new therapies looking to demonstrate cost-effectiveness, according to Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review. In doing so, stakeholders can better understand the balance between innovation and affordability.
Health technology assessment (HTA) is a tool that helps to objectively evaluate evidence, which levels the playing field for new therapies looking to demonstrate cost-effectiveness, according to Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review. In doing so, stakeholders can better understand the balance between innovation and affordability.
Transcript (slightly modified)
What impact can health technology assessment have on budgeting and innovation?
Well, HTA is supposed to be a tool to help decision making. It by itself doesn’t make decisions; it’s supposed to help foster the right kinds of decisions. We have to decide how we are going to balance the incentives for innovation with the affordability for the healthcare system, and that’s a tension that every health system around the world faces today, but they’ve also faced it in the past.
What HTA does is it tries to make sure that it takes an objective and transparent approach to judging the evidence, so that the discussions about how we innovate and how we price and how we pay for services can be held on the basis of fairly evaluated evidence. It helps raise the bar and make sure that everybody is playing on the same level playing field.
In many cases, it will highlight tension between innovation and affordability, but that’s what we need. We need it clearly highlighted, we need it fairly discussed, and so I think HTA has a really important role to play in supporting that kind of conversation.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
